Complement inhibitors
The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
1. An isolated cDNA molecule comprising a nucleotide sequence encoding a complement inhibitor, wherein said complement inhibitor is:
a) a protein comprising the amino acids 19 to 168 of SEQ ID NO: 2;
b) a protein comprising the amino acid sequence of SEQ ID NO: 2;
c) the protein of a) or b) having at least 95% sequence identity to SEQ ID NO: 2; or
d) a fragment of the complement inhibitor polypeptide of SEQ ID NO: 2, wherein said fragment comprises six cysteine residues that are spaced relative to each other at a distance of 32 amino acids apart, 62 amino acids apart, 28 amino acids apart, 1 amino acid apart, and 21 amino acids apart as arranged from the amino terminus to the carboxyl terminus of SEQ ID NO: 2, wherein the complement inhibitor inhibits cleavage of C5 by classical and alternative C5 convertases.
2. The isolated cDNA of claim 1 comprising nucleotides 55 to 507 of the nucleotide sequence of SEQ ID NO: 1.
3. The isolated cDNA of claim 1 comprising nucleotides 1 to 507 of the nucleotide sequence of SEQ ID NO: 1.
4. The isolated cDNA of claim 1 consisting of nucleotides 5553 to 507 of the nucleotide sequence of SEQ ID NO: 1.
5. The isolated cDNA of claim 1 consisting of nucleotides 1 to 507 of the nucleotide sequence of SEQ ID NO: 1.
6. An isolated antisense nucleic acid molecule which hybridises under high stringency hybridisation conditions of 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5×Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1×SSC at approximately 65° C. to the full length of the isolated cDNA molecule of claim 1 .
7. A composition comprising the isolated cDNA of claim 1 in conjunction with a pharmaceutically acceptable carrier.
8. A vector comprising the isolated cDNA of claim 1 .
9. A vector comprising the isolated cDNA of claim 2 .
10. A vector comprising the isolated cDNA of claim 3 .
11. A vector comprising the isolated cDNA of claim 4 .
12. A vector comprising the isolated cDNA of claim 5 .
13. An isolated host cell comprising the isolated cDNA of claim 1 .
14. An isolated host cell comprising the isolated cDNA of claim 2 .
15. An isolated host cell comprising the isolated cDNA of claim 3 .
16. An isolated host cell comprising the isolated cDNA of claim 4 .
17. An isolated host cell comprising the isolated cDNA of claim 5 .
18. An isolated host cell comprising the isolated cDNA of claim 6 .
19. An isolated host cell comprising the vector of claim 8 .
20. An isolated cDNA molecule comprising a 507-nucleotide sequence that encodes a complement inhibitor having at least 95% amino acid sequence identity to SEQ ID NO:2.
21. An isolated cDNA molecule comprising a 507-nucleotide sequence that encodes a complement inhibitor having an amino acid sequence of SEQ ID NO:2.
22. An isolated cDNA molecule comprising a 453-nucleotide sequence that encodes a mature form of complement inhibitor having at least 95% amino acid sequence identity to amino acids 19 to 168 of SEQ ID NO:2.
23. An isolated cDNA molecule comprising a 453-nucleotide sequence that encodes a mature form of complement inhibitor having an amino acid sequence identical to amino acids 19 to 168 of SEQ ID NO:2.